Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism

Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease, had no approved pharmacological agents yet. Obeticholic acid (OCA), a novel bile acid derivative, was demonstrated to ameliorate NAFLD-related manifestations. Regarding the role of gut-liver axis in liver disease devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jianjun, Sun, Jiayi, Yu, Jiangkun, Chen, Hang, Zhang, Dan, Zhang, Tao, Ma, Yicheng, Zou, Chenggang, Zhang, Zhigang, Ma, Lanqing, Yu, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232493/
https://www.ncbi.nlm.nih.gov/pubmed/37258543
http://dx.doi.org/10.1038/s41522-023-00399-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232493/
https://www.ncbi.nlm.nih.gov/pubmed/37258543
http://dx.doi.org/10.1038/s41522-023-00399-z

Ejemplares similares